Pharmaceutical Analytical Testing Outsourcing Market – By Services (Bioanalytical Testing [Clinical, Non-clinical], Method Development & Validation, Stability Testing) Product Type (API, Additive, Finished Product), End-user & Forecast, 2024 – 2032
Pharmaceutical analytical testing outsourcing market size is estimated to register 8% CAGR between 2024 and 2032. The increasing complexity of pharmaceutical products and stringent regulatory requirements is necessitating comprehensive analytical testing throughout the drug development and manufacturing process.
Outsourcing analytical testing services enables pharmaceutical companies to access specialized expertise, advanced technologies, and state-of-the-art facilities for streamlining operations and reducing time-to-market. For instance, in November 2023, RSSL, a CRO (contract research organization) for food and pharmaceuticals, inaugurated its state-of-the-art analytical testing facility to fulfil increased client requirements in the life science, healthcare, food, and consumer goods industries.
The growing trend of outsourcing non-core activities for focusing on core competencies is driving the adoption of pharmaceutical analytical testing outsourcing services. By outsourcing analytical testing tasks to third-party service providers, pharmaceutical companies are allocating resources more strategically, prioritizing R&D initiatives, and accelerating innovation in drug development, creating opportunities for the market growth.
The pharmaceutical analytical testing outsourcing industry is classified based on service, product type, end-user and region.
The industry size from the additives product type segment is projected to witness 8.4% CAGR through 2032. The increasing complexity and diversity of additives used in pharmaceutical formulations is necessitating specialized analytical testing to ensure product quality, safety, and compliance with regulatory standards. Outsourcing analytical testing services allows pharmaceutical companies to access expertise in additive analysis, including identification, quantification, and characterization of additives, without the need for significant investment in specialized equipment and personnel training.
The biopharmaceutical companies end-user segment in the pharmaceutical analytical testing outsourcing market is anticipated to observe an 8.4% CAGR during 2024-2032. The rising risks of biopharmaceutical products, including biologics, biosimilars, and gene therapies is requiring specialized analytical testing to ensure product quality, safety, and efficacy. Outsourcing partners also offer a comprehensive range of analytical testing capabilities tailored to the unique requirements of biopharmaceuticals, including cell-based assays, purity assessments, and glycan analysis.
Asia Pacific pharmaceutical analytical testing outsourcing industry size will record 8.4% growth rate over 2024-2032, attributed to the burgeoning pharmaceutical sector and increasing investments in R&D activities. The adoption of contract research and manufacturing services by domestic and multinational pharmaceutical companies in the region has significantly risen. Growing regulatory harmonization efforts and increasing acceptance of outsourcing as a strategic business model in the pharmaceutical space will stimulate the regional industry growth.
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Globalization of the pharmaceutical industry
3.2.1.2 Regulatory framework
3.2.1.3 Growing advancements in analytical instrumentations
3.2.1.4 Increasing outsourcing trends
3.2.2 Industry pitfalls & challenges
3.2.2.1 Quality concerns and risk mitigation
3.2.2.2 Confidentiality and intellectual property protection
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Service, 2018 - 2032 ($ Million)
5.1 Key trends
5.2 Bioanalytical testing
5.2.1 Clinical
5.2.2 Non-clinical
5.3 Method development & validation
5.3.1 Extractable & leachable
5.3.2 Impurity method
5.3.3 Technical consulting
5.3.4 Other method development & validation services
5.4 Stability testing
5.4.1 Drug substance testing
5.4.2 Stability indicating method validation
5.4.3 Accelerated stability testing
5.4.4 Photostability testing
5.4.5 Other stability testing services
5.5 Other services
Chapter 6 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Million)
6.1 Key trends
6.2 Active pharmaceutical ingredient (API)
6.3 Additives
6.4 Finished products
Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Million)
7.1 Key trends
7.2 Pharmaceutical companies
7.3 Biopharmaceutical companies
7.4 Academics & research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 BA Sciences
9.2 Charles River Laboratories International, Inc.